Company Profile
Renalytix AI Stock Price, News & Analysis
- Ticker:
- RNLX
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United Kingdom and traded in the U
Why the stock is moving
Current closing-price context is not available for RNLX.
Company overview
Business overview
Renalytix AI was a diagnostics and data company focused on kidney disease risk assessment and digital biomarkers before its restructuring and decline. Its platform aimed to help detect kidney disease earlier.
Geographic Base and Sector Classification
Headquartered in the United Kingdom and traded in the U.S., Renalytix sat in diagnostics and health data.
Business Model Characteristics
The company depended on test adoption, reimbursement, and the ability to scale a kidney-diagnostics platform.
Position Within the Biotechnology Landscape
Renalytix belongs to the historical diagnostics-and-data category rather than the current live public-company set.
Future catalysts
Renalytix’s catalysts are kidney-risk testing adoption, reimbursement, and whether the company can keep building clinical workflow usage. Investors will watch for evidence that the product is becoming more embedded.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Renalytix AI do?
Renalytix AI was a diagnostics and data company focused on kidney disease risk assessment and digital biomarkers before its restructuring and decline. Its platform aimed to help detect kidney disease earlier.
On which exchange is RNLX stock listed?
Renalytix AI (RNLX) is associated with NASDAQ, United Kingdom and traded in the U, MedTech.
What is Renalytix?
Renalytix’s catalysts are kidney-risk testing adoption, reimbursement, and whether the company can keep building clinical workflow usage.
Which conditions is Renalytix AI targeting with Renalytix?
Renalytix’s catalysts are kidney-risk testing adoption, reimbursement, and whether the company can keep building clinical workflow usage.
How does Renalytix AI describe recent progress with Renalytix?
Renalytix’s catalysts are kidney-risk testing adoption, reimbursement, and whether the company can keep building clinical workflow usage.
What is Investors?
Investors will watch for evidence that the product is becoming more embedded.
What should investors watch for with Investors?
Investors will watch for evidence that the product is becoming more embedded.
What future catalysts are investors watching for Renalytix AI?
Renalytix’s catalysts are kidney-risk testing adoption, reimbursement, and whether the company can keep building clinical workflow usage. Investors will watch for evidence that the product is becoming more embedded.